PA8606001A1 - Saquinavir mesilato, forma de dosificacion oral - Google Patents

Saquinavir mesilato, forma de dosificacion oral

Info

Publication number
PA8606001A1
PA8606001A1 PA20048606001A PA8606001A PA8606001A1 PA 8606001 A1 PA8606001 A1 PA 8606001A1 PA 20048606001 A PA20048606001 A PA 20048606001A PA 8606001 A PA8606001 A PA 8606001A PA 8606001 A1 PA8606001 A1 PA 8606001A1
Authority
PA
Panama
Prior art keywords
saquinavir
mesilato
mesilate
dosage form
oral dosage
Prior art date
Application number
PA20048606001A
Other languages
English (en)
Inventor
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Martin Howard Infeld
Antonio A Albano
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8606001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8606001A1 publication Critical patent/PA8606001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PROPORCIONA UNA FORMA DE DOSIFICACION FARMACEUTICA SOLIDA UNITARIA ORAL DE SAQUINAVIR MESILATO QUE CONTIENE EL SAQUINAVIR MESILATO MICRONIZADO EN UNA CANTIDAD COMPRENDIDA ENTRE 250 MG Y 800 MG, CALCULADA COMO BASE LIBRE, Y UN AGLUTINANTE FARMACEUTICAMENTE ACEPTABLE, UN DESINTEGRANTE Y UN EXCIPIENTE SOLUBLE EN AGUA. SE PROPORCIONA UNA FORMA DE DOSIFICACION SOLIDA UNITARIA DE SAQUINAVIR MESILATO QUE CONTIENE DEL 60% A 80% DE SAQUINAVIR MESILATO MICRONIZADO BASADO EN LA SAL MESILATO, DEL 4% AL 8% DE AGLUTINANTE SOLUBLE EN AGUA, UN DESINTEGRANTE Y UN EXCIPIENTE, EN LA QUE CADA PORCENTAJE SE REFIERE AL PESO DEL NUCLEO.
PA20048606001A 2003-07-11 2004-07-07 Saquinavir mesilato, forma de dosificacion oral PA8606001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48660003P 2003-07-11 2003-07-11
US56820404P 2004-05-05 2004-05-05

Publications (1)

Publication Number Publication Date
PA8606001A1 true PA8606001A1 (es) 2005-03-03

Family

ID=34068244

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048606001A PA8606001A1 (es) 2003-07-11 2004-07-07 Saquinavir mesilato, forma de dosificacion oral

Country Status (24)

Country Link
US (2) US20050009811A1 (es)
EP (1) EP1646369B1 (es)
JP (2) JP4608488B2 (es)
KR (2) KR100767271B1 (es)
AU (1) AU2004255436B2 (es)
BR (1) BRPI0412523A (es)
CA (1) CA2531486C (es)
CO (1) CO5640069A2 (es)
CR (1) CR8172A (es)
EA (1) EA015349B1 (es)
EC (1) ECSP066274A (es)
HK (1) HK1089959A1 (es)
IL (1) IL172890A (es)
MA (1) MA27904A1 (es)
MX (1) MXPA06000363A (es)
MY (1) MY140413A (es)
NO (1) NO20060313L (es)
NZ (1) NZ544585A (es)
PA (1) PA8606001A1 (es)
PE (1) PE20050247A1 (es)
RS (1) RS20060009A (es)
TN (1) TNSN06003A1 (es)
TW (1) TWI356711B (es)
WO (1) WO2005004836A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
EP2851075B1 (en) 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5547683A (en) * 1992-10-09 1996-08-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for producing microgranulated particle
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
AU3705799A (en) * 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
IL143691A0 (en) * 1998-12-17 2002-04-21 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태

Also Published As

Publication number Publication date
KR100767271B1 (ko) 2007-10-17
TWI356711B (en) 2012-01-21
WO2005004836A2 (en) 2005-01-20
JP2009501694A (ja) 2009-01-22
TW200505504A (en) 2005-02-16
CA2531486A1 (en) 2005-01-20
MY140413A (en) 2009-12-31
US20050009811A1 (en) 2005-01-13
PE20050247A1 (es) 2005-04-13
TNSN06003A1 (en) 2007-10-03
KR20070087194A (ko) 2007-08-27
HK1089959A1 (en) 2006-12-15
EP1646369A2 (en) 2006-04-19
NZ544585A (en) 2008-04-30
WO2005004836A3 (en) 2005-05-12
CA2531486C (en) 2012-10-02
CO5640069A2 (es) 2006-05-31
CR8172A (es) 2006-10-04
BRPI0412523A (pt) 2006-09-19
NO20060313L (no) 2006-02-09
IL172890A (en) 2013-11-28
AU2004255436A1 (en) 2005-01-20
RS20060009A (en) 2008-06-05
US20090054481A1 (en) 2009-02-26
ECSP066274A (es) 2006-10-25
JP2010280707A (ja) 2010-12-16
EP1646369B1 (en) 2019-04-10
IL172890A0 (en) 2006-06-11
KR20060056320A (ko) 2006-05-24
MA27904A1 (fr) 2006-05-02
EA015349B1 (ru) 2011-06-30
AU2004255436B2 (en) 2006-11-30
MXPA06000363A (es) 2006-03-28
EA200600156A1 (ru) 2006-08-25
JP4608488B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
AR057812A1 (es) Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
UY28132A1 (es) Derivados de pirrolopirimidina
AR019935A1 (es) Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
ES2255287T3 (es) Composiciones para el tratamiento de la leucemia linfocitica cronica.
CO5390076A1 (es) Composiciones farmaceuticas
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
PE20050066A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CY1116465T1 (el) Φαρμακοτεχνικη μορφη για προφυλαξη ασθενειων της στοματικης κοιλoτητας
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
ECSP066274A (es) Saquinavir mesilato, forma de dosificacion oral
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada